Evidence map›Paper›PMID 39415081›Full record

ArticleBMC infectious diseases2024

Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19.

Nastaran Injinari, Samira Asadollahi, Fateme Sefid, Maedeh Arshadi, Saeedeh Sadat Hosseini, Hamed Ghoshouni, Fatemeh Soltani, Nasim Namiranian, Mohammad Hasan Sheikhha, Fatemeh Aghaeimeybodi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nastaran InjinariDiabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID http://orcid.org/0000-0001-5524-5388
Samira AsadollahiResearch Center for Food Hygiene and Safety, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID http://orcid.org/0000-0002-6712-0504
Fateme SefidDepartment of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID http://orcid.org/0000-0003-0867-9305
Maedeh ArshadiDepartment of Epidemiology and Biostatistics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID http://orcid.org/0000-0001-7696-5042
Saeedeh Sadat HosseiniResearch Center for Food Hygiene and Safety, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID http://orcid.org/0000-0002-9613-1296
Hamed GhoshouniDiabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID http://orcid.org/0000-0001-8949-2256
Fatemeh SoltaniDiabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID http://orcid.org/0009-0006-3694-657X
Nasim NamiranianDiabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID http://orcid.org/0000-0002-5133-6204
Mohammad Hasan SheikhhaAbortion Research Centre, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Science, Yazd, Iran.ORCID http://orcid.org/0000-0002-3734-8970
Fatemeh AghaeimeybodiDepartment of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Daneshjoo Blvd, Yazd, Iran. drmeybodi@gmail.com.ORCID http://orcid.org/0000-0002-5132-2494

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough several genetic biomarkers have been reported in the tocilizumab (TCZ) response in rheumatoid arthritis, no studies have addressed the pharmacogenomics effect of TCZ in COVID-19.

methodsIn this prospective longitudinal study, 95 individuals with severe COVID-19 were selected between 2020-2022. The recovery process was measured at 24 h, 48 h, and 10 days before and after taking TCZ. All participants were genotyped using RFLP-PCR. Different genotypes of FCGR2A rs1801274 and IL-6R rs2228145 were compared in terms of the recovery process.

results43.2% of patients were male and 56.8% were female with an average age of 58.20(± 16.214) years. The GA genotype for FCGR2A rs1801274 increased the risk of death (OR = 2.83, P = 0.038) and ventilation (OR = 2.71, P = 0.047) in TCZ-treated individuals. However, there was no risk of death and ventilation with IL-6R rs2228145 (P > 0.05). Additionally, docking analysis showed that not only IL6R but also FCGR2A can be a ligand for TCZ.

conclusionThis study provides valuable insights into the impact of genetic variations on the response rate of TCZ in COVID-19 patients. The GA genotype for FCGR2A rs1801274 was associated with poor treatment outcomes.

Indexed as

Antibodies, Monoclonal, HumanizedCOVID-19COVID-19 Drug TreatmentPolymorphism, Single NucleotideReceptors, IgGReceptors, Interleukin-6SARS-CoV-2AdultAgedFemaleGenotypeHumansIranLongitudinal StudiesMaleMiddle AgedAntibodies, Monoclonal, HumanizedFCGR2A protein, humanIL6R protein, humanReceptors, IgGReceptors, Interleukin-6tocilizumabCOVID-19FCGR2AIL-6 receptorPolymorphismTocilizumab

Identifiers

PMID39415081
PMCPMC11481263

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.